Overview of Хенофальк

Quick Facts

Property	Description
Active Ingredient	Chenodeoxycholic Acid (CDCA)
Form	Oral Capsule (Hard Gelatin)
Pharmacological Class	Cholelitholytic Agent
General Purpose	Modifying bile chemistry to dissolve cholesterol formations
Origin	Semi-synthetic (Bile Acid Derivative)

Хенофальк is a pharmaceutical product, classified as a Cholelitholytic Agent and a Bile Acid Derivative, that is administered as an oral capsule. This medication is consistently categorized as a prescription-only substance, reflecting its systemic action and required medical oversight. Its foundational purpose is to act internally to address chemical imbalances within the biliary system.

The product contains a single active substance, Chenodeoxycholic Acid (CDCA), which is the compound utilized in this formulation. This identification establishes its place within the global pharmaceutical nomenclature.

What Type of Medicine is Хенофальк? (Identity and Classification)

Хенофальк is defined as a drug that acts by chemically altering the solubility of bile components, a function central to its classification as a Cholelitholytic Agent. As a therapeutic bile acid, Chenodeoxycholic Acid is clinically recognized for its ability to modify biliary content. This classification means the medicine is designed to work at a chemical level to normalize gallbladder and bile duct function.

The medication is a single-component product whose molecular structure is based on naturally occurring bile acids, leading to its description as semi-synthetic. This characteristic underscores its unique positioning, utilizing a chemically stable derivative to achieve a systemic effect.

The General Purpose of Chenodeoxycholic Acid (High-Level Benefit)

The core purpose of Chenodeoxycholic Acid is to normalize the composition of bile by making it less saturated with cholesterol. This is achieved through the physiological action of suppressing the secretion of excess cholesterol from the liver into the bile.

By promoting the desaturation of bile, Хенофальк helps create an internal environment where solid cholesterol deposits can be solubilized over time. This targeted modification of bile chemistry offers a systemic approach aimed at improving the functional state of the biliary system, a typical scenario being its use in patients suitable for non-surgical management of cholesterol-related issues. CDCA administration leads to a significant reduction in bile cholesterol saturation. Consequently, the medication directly influences the key factor driving cholesterol-related issues.

Regulatory References

What side effects are possible with Хенофальк?

Official Safety Profile of Chenodeoxycholic Acid

The safety profile for Chenodeoxycholic Acid (the active substance in Хенофальк) is based on classifications defined by government regulatory authorities, focusing primarily on effects within the gastrointestinal and hepatobiliary systems.

Adverse Reaction Classification

Adverse reactions are classified by frequency, with the most common effects related to the digestive system:

Classification	System-Organ Class	Examples from Regulatory Labeling
Very Common	Gastrointestinal Disorders	Diarrhea or loose stools (often dose-dependent)
Common	Hepatobiliary Disorders	Transient elevation of serum transaminases (liver enzymes)
Common	Gastrointestinal Disorders	Abdominal pain, nausea

Time-Related and Serious Safety Characteristics

Regulatory labeling notes that both the gastrointestinal effects and the transient elevations in liver enzymes are often observed at the start of treatment or during periods of dose escalation.

While these enzyme increases are usually reversible, the most serious official safety concern is the potential for Hepatotoxicity (severe liver damage), particularly with high doses or in patients with pre-existing conditions. Due to this risk, official prescribing information mandates regular monitoring of liver function tests during therapy.

Population and Condition Safety Restrictions

Chenodeoxycholic Acid is subject to specific safety constraints. It is contraindicated in conditions such as severe hepatic impairment (severe chronic liver disease), non-functioning gallbladder, and acute inflammation of the biliary tract. Furthermore, official safety notes require women of childbearing potential to use effective, non-hormonal contraception during the course of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Chenodeoxycholic Acid (Хенофальк) defines the overdose profile primarily through the risk of hepatotoxicity (serious liver problems) and resulting clinical signs. Since the drug is processed by the liver, an acute overdose exacerbates dose-related effects and may cause severe liver damage.

Documented manifestations of overdose or severe toxicity include systemic signs of liver impairment such as jaundice, dark-colored urine, pruritus (itching), fatigue, and unexplained bruising or bleeding. Gastrointestinal symptoms like severe diarrhea, nausea, and abdominal pain are also officially noted as presentations that may be exacerbated in overdose situations.

Urgent medical attention is required immediately upon the observation of any such clinical signs or symptoms consistent with hepatotoxicity. Regulators mandate that treatment must be discontinued immediately if signs of liver impairment occur, or if laboratory monitoring reveals that liver transaminase (ALT/AST) levels are greater than 3 times the upper limit of normal or total bilirubin levels are greater than 2 times ULN.

Following a suspected overdose event, official instructions require the institution of general supportive measures and continuous patient monitoring. This monitoring includes assessing liver transaminase and total bilirubin levels until they return to baseline values. No specific antidote is described in the official prescribing information.

Therapeutic Uses of Хенофальк

What Хенофальк Treats: Main Uses and Benefits

The primary application of Хенофальк's active substance (Chenodeoxycholic acid) is applied across domains where additional symptomatic support is needed, particularly when digestive and biliary symptoms create noticeable discomfort. It is commonly used in situations involving acute, symptomatic distress to help ease the overall symptom load.

The therapeutic category to which this medication belongs is considered relevant for conditions that present with a heightened symptomatic burden, such as Primary Biliary Cholangitis (PBC) and for the dissolution of radiolucent gallstones. This use is considered relevant in contexts involving heightened systemic burden.

The medication is commonly used during acute symptomatic episodes or phases when the patient experiences increased discomfort or tension, often related to the biliary or hepatic systems. It helps manage the intensity of symptoms that may interfere with daily functioning. It is applied in addressing disruptive manifestations, which assists with maintaining functional stability and supports patients during difficult episodes.

“It provides support that helps ease the overall symptom burden, and may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Used for managing Symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

Хенофальк (chenodeoxycholic acid) is a medication that is not suitable for all patients. Regulatory guidelines establish strict eligibility criteria, primarily focusing on liver function and the state of the biliary system.

Formal Contraindications (Must Not Use):

Contraindicated Group	Restriction Context
Liver/Biliary Impairment	Known hepatocyte dysfunction or severe liver disease (e.g., cirrhosis), bile duct abnormalities, or complete biliary obstruction.
Gastrointestinal Disease	Presence of peptic ulcer or inflammatory bowel disease (such as Crohn's disease).
Hypersensitivity	Known allergy to chenodeoxycholic acid or any of its excipients.
Pregnancy/Lactation	Use is contraindicated during pregnancy and in women who may become pregnant unless using effective contraception; use during breast-feeding is generally not recommended.

Other Eligibility Restrictions:

Gallstones: Not effective for all gallstone types; use is contraindicated for calcified (radiopaque) stones and for a non-functioning gallbladder. The medication should be reserved for carefully selected patients, and treatment requires systematic monitoring of liver function tests.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically relevant interaction patterns of Chenodeoxycholic Acid (CDCA), the active ingredient in Хенофальк, as documented in official government regulatory information.

Documented Pharmacokinetic and Pharmacodynamic Effects

Interaction Type	Interacting Substance/Class	Regulatory Constraint and Outcome
Pharmacokinetic	Bile Acid Sequestering Agents (e.g., Cholestyramine, Colestipol)	Co-administration is formally restricted; avoid concomitant use to prevent reduction in CDCA absorption.
Pharmacokinetic	Aluminum-based Antacids (containing aluminum hydroxide)	Co-administration is formally restricted; avoid concomitant use due to binding, leading to reduced CDCA exposure.
Pharmacodynamic	Coumarin and its derivatives (e.g., Warfarin)	Co-administration requires close procedural monitoring of prothrombin time (PT) to manage the effect on coagulation status.

Interaction-Related Restrictions

The interaction with both bile acid sequestering agents and aluminum-based antacids is one of pharmacokinetic interference, where these binding substances reduce the systemic exposure of CDCA. The official regulatory instruction to avoid concomitant use establishes a mandatory administrative separation requirement between Хенофальк and these agents. For coumarin derivatives, the interaction is addressed by a procedural constraint, where coagulation markers must be routinely monitored.

Mechanism of Action

Targeting FXR to Suppress Hepatic Cholesterol Production

The core mechanism involves Chenodeoxycholic Acid (CDCA) acting as an agonist for the Farnesoid X Receptor (FXR), a nuclear receptor that governs metabolic balance. Activation of FXR initiates a regulatory feedback loop that transcriptionally suppresses key enzymes, such as CYP7A1 and HMG-CoA reductase. This molecular cascade reduces the synthesis and secretion of cholesterol from the liver into the bile, which is a required step in achieving cholesterol desaturation.

Enhancing Bile's Solubilization Capacity

By lowering cholesterol output while simultaneously increasing the proportion of highly efficient bile acids (CDCA itself) in the circulating bile fluid, the medication fundamentally alters the biliary chemical environment. This modification results in an increase in the bile's capacity to dissolve cholesterol, transitioning the bile fluid to a cholesterol-desaturated state capable of acting as a solvent. This state facilitates the transfer of cholesterol molecules from pre-existing solid deposits into the micellar phase.

Mechanistic Constraints and Prerequisites

This dissolution mechanism is rigidly constrained by the chemistry of the target material; the mechanism is confined to, or relevant only for, non-calcified, cholesterol-based formations. Furthermore, an anatomically and functionally intact gallbladder is required to maintain the necessary concentration and circulation of CDCA-rich bile for the mechanism to operate.

Dosage and Administration Information

How to Use Chenodeoxycholic Acid (Хенофальк)

The administration of Chenodeoxycholic Acid follows established parameters regarding the route, dosing schedule, and specific intake conditions.

The medication is designed for oral administration only, typically provided as a hard capsule or tablet of 250 mg strength. The total daily quantity is prescribed in divided doses, commonly administered two or three times daily depending on the intended use. The duration of therapy is generally long-term; for gallstone dissolution, the course may extend for up to 24 months.

Dosage Regimens

Dosing is non-uniform and depends on the specific, approved indication:

Gallstone Dissolution: A weight-based regimen is employed, ranging from 13 to 16 mg/kg per day. Dosing is often initiated with a lower amount and increased incrementally each week until the target maintenance dose is reached.
Cerebrotendinous Xanthomatosis (CTX): The typical maintenance dose is 750 mg per day, administered in three divided doses, with a maximal daily amount of 1,000 mg.

Administration Rules and Adjustments

The capsule or tablet must be swallowed whole with water and must not be crushed or chewed. The medicine can be taken with or without food. If a dose is missed, the standard protocol is to skip it and resume the normal schedule; a double dose should not be taken. For older adults (65 and over), no specific dose adjustment is generally necessary. Dose adjustment or interruption is a requirement based on the periodic monitoring of liver function tests and disease-specific metabolic markers.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Хенофальк

Хенофальк (Chenodeoxycholic Acid) has been studied in two primary research areas: the dissolution of cholesterol gallstones and the management of the rare metabolic condition, Cerebrotendinous Xanthomatosis (CTX). The evidence base is drawn from a combination of controlled trials, observational cohorts, and long-term registry data.

Research for Cholesterol Gallstone Dissolution

Research exploring gallstone dissolution was largely conducted through Randomized Controlled Trials (RCTs) in adult populations. These studies examined outcomes related to radiological endpoints, monitoring the disappearance or reduction in size of the stones using imaging, and biochemical outcomes, tracking changes in the cholesterol saturation level of bile. Studies reported measurements of complete gallstone dissolution observed in some study participants.

What remains uncertain:

Limited Response: Evidence suggests that the dissolution rates observed in some studies were low.
Recurrence: Long-term follow-up data describes a pattern where gallstone recurrence was observed in some studies after the medication was stopped. The long-term durability of the change in bile composition is not fully established.

Research for Cerebrotendinous Xanthomatosis (CTX)

Due to the rarity of CTX, research exploring its management has primarily utilized long-term retrospective cohort studies and open-label trials, which often include both adults and pediatric patients. The studies monitored biochemical outcomes, specifically tracking the levels of abnormal cholesterol metabolites (like cholestanol), and neurological outcomes using standardized disability scores. Research reports measurements describing a change in the pathological biochemical markers toward normalization in the observed study populations.

Evidence in Special Populations: Evidence is explicitly available for pediatric patients with CTX. Findings from observational studies describe patterns associated with earlier administration in younger patients. However, for the gallstone indication, specific long-term data for older adults or patients with multiple comorbidities is generally insufficient.

The Research Landscape: Areas of Uncertainty

For CTX, due to the rarity of the disease, sample sizes were modest in many trials, meaning the full range of outcomes and long-term effects on the most complex neurological symptoms are not fully established. For gallstone dissolution, the main areas of uncertainty relate to the limited and mixed findings regarding complete stone disappearance, as study results were highly dependent on patient characteristics.

Frequently Asked Questions (FAQ)

Common questions about Хенофальк (FAQ)

Q: How quickly can a person expect to see any changes or improvements?

According to official administration advice, initial monitoring for the effectiveness of gallstone dissolution is generally scheduled after 6 to 9 months of treatment using imaging tests. Study findings have indicated that among participants who later achieved complete gallstone dissolution, at least a partial reduction in stone size was often observed during this early imaging check-up.

Q: How long does it usually take for gallstones to potentially dissolve with this medicine?

Official information indicates that the duration of therapy for gallstone dissolution is generally long-term, described as a course that may extend for up to 24 months of continuous treatment.

Q: Does Хенофальк work by stopping the liver from producing cholesterol?

Regulatory texts describe the drug's mechanism as working to reduce the synthesis and secretion of cholesterol from the liver into the bile. This action helps to desaturate the bile, creating a chemical environment that allows cholesterol formations to dissolve. It works by reducing production, not stopping it entirely.

Q: If I am taking a blood thinner, is there a known interaction with Хенофальк?

Official documents list an interaction with Coumarin and its derivatives, which is a class of medications that includes certain blood thinners. Due to the potential for interaction, regulatory constraints require close procedural monitoring of the patient's coagulation status (measured by prothrombin time or PT) while taking both medicines.

Q: Does Хенофальк interact with statins or other cholesterol-lowering medicines?

Regulatory labeling notes that substances that increase biliary cholesterol secretion, such as estrogen and oral contraceptives, may potentially counteract the drug's effectiveness. While statins (a common type of cholesterol-lowering drug) are not specifically listed as an interaction, the principle of potential counteraction exists with other lipid-lowering agents.

Q: What are the general guidelines for storing Хенофальк capsules/tablets?

The official requirements state that the medicine must be stored at a temperature not exceeding 30 C. It must also be kept in its original package to ensure protection from moisture. It is mandatory to keep this medicine out of the sight and reach of children.

Q: Is Хенофальк the same as ursodeoxycholic acid (UDCA) drugs?

No. Both are bile acid derivatives, but they are different substances. Chenodeoxycholic Acid (Хенофальк) is described in official nomenclature as a primary bile acid, while ursodeoxycholic acid (UDCA) is a different bile acid derivative used for similar, but not identical, therapeutic purposes.

Q: What is the difference between Хенофальк and other drugs for dissolving gallstones?

The medicine is officially classified as a Cholelitholytic Agent. Its mechanism works by chemically altering the solubility of bile components, specifically by suppressing the secretion of excess cholesterol from the liver to create a bile composition that can dissolve cholesterol formations.

Q: Can Хенофальк be taken long-term for chronic liver conditions?

The drug is officially indicated for the long-term treatment of the chronic metabolic liver condition Cerebrotendinous Xanthomatosis (CTX). However, official guidelines list certain other chronic liver conditions, such as severe hepatic impairment or cirrhosis, as formal contraindications for use.

Q: Is it normal to experience hair thinning or hair loss while on this medication?

Hair loss or thinning is not explicitly listed as a Very Common or Common adverse reaction in the Chenodeoxycholic Acid regulatory safety profile.

Q: Is Хенофальк suitable for children or adolescents, according to official documents?

The safety and effectiveness for the gallstone dissolution indication in children and adolescents have not been established. However, official documents confirm that it is approved for use in pediatric patients for the treatment of the rare metabolic condition Cerebrotendinous Xanthomatosis (CTX).

Q: Can Хенофальк affect how other bile acid medications work?

Co-administration with Bile Acid Sequestering Agents (another class of drug that acts on bile) is formally restricted. This is due to pharmacokinetic interference, where these binding substances reduce the absorption of Chenodeoxycholic Acid into the system.

Q: What should I know about severe abdominal pain while taking Хенофальк?

Official documentation notes that abdominal pain is a Common side effect. The prescribing information includes warnings regarding potential gallstone complications, with symptoms that may include severe or acute abdominal pain. Official documents generally state that symptoms of this nature should be brought to the attention of a healthcare professional.

Q: Is Хенофальк available without a prescription in any region?

Chenodeoxycholic Acid is consistently categorized by government regulatory agencies as a prescription-only substance. Its systemic action and monitoring requirements mean it must be administered under medical oversight.

Q: Can Хенофальк be used for other gastrointestinal issues like irritable bowel syndrome (IBS)?

Use of the medicine is defined by its approved indications (gallstone dissolution and CTX). Official documents list specific gastrointestinal diseases, such as Inflammatory Bowel Disease (like Crohn's disease) and Peptic Ulcer, as formal contraindications for use.

Q: Are there different strengths or forms of Хенофальк available (e.g., capsule vs. suspension)?

The drug is officially available in a 250 mg strength, typically supplied as an oral hard capsule or tablet. However, regulatory administration advice describes conditions where an extemporaneously prepared suspension (a liquid form) may be used.

Q: What are the reported effects of Хенофальк in elderly patients?

Official prescribing information states that no specific dose adjustment is generally necessary for older adults ( 65 and over). The drug's safety profile focuses on general side effects and conditions that apply across adult populations.

Q: What are the signs of a possible allergic reaction to the drug?

Official information lists Hypersensitivity (severe allergy) to the drug as a formal contraindication. Signs of an allergic reaction often described in drug labeling include skin rash, hives, and swelling of the face, lips, tongue, or throat.

Q: Does Хенофальк help prevent new gallstones from forming?

Official research overview describes a pattern where gallstone recurrence was observed in some studies after the medication was stopped. This suggests the long-term durability of the bile composition change and the effectiveness of prevention are not fully established in all cases.

Q: What happens if a patient stops taking Хенофальк suddenly?

Regulatory research documentation notes that gallstone recurrence has been detected in study patients after treatment was discontinued.

Q: Does Хенофальк affect bone density or risk of fractures?

Research in patients with the metabolic condition Cerebrotendinous Xanthomatosis (CTX), a population that often presents with low bone density, has described patterns of improvement in bone mineral content following long-term treatment with the drug.

Q: Is Хенофальк approved for use in all types of liver disease?

No. The medicine is contraindicated in conditions such as severe hepatic impairment (severe chronic liver disease) and complete biliary obstruction. Its use is limited to officially approved indications, such as gallstone dissolution and CTX.

Q: Can this medication cause headaches or dizziness?

Headache and dizziness are not listed as Very Common or Common adverse effects in the core regulatory safety profile. The most common effects are generally related to the gastrointestinal system.

Q: What research themes exist about Хенофальк's use in patients with other bowel diseases like Crohn's?

Official documents list Inflammatory Bowel Disease (such as Crohn's disease) as a formal contraindication for use. This defines an area where the drug should not be administered, rather than an area of approved research.

Q: Is there a maximum time frame for taking Хенофальк to dissolve gallstones?

The official duration of therapy for gallstone dissolution is generally long-term, described as a course that may extend for up to 24 months of continuous treatment.

Q: Does Хенофальк interact with hormone replacement therapy (HRT)?

Regulatory labeling notes that Estrogen and oral contraceptives can increase the incidence of cholesterol gallstones. Therefore, these substances may counteract the drug's effectiveness when used for gallstone dissolution.

How should Хенофальк be stored and disposed of?

How to Store and Dispose of Хенофальк? (Official Requirements)

The storage and disposal of Хенофальк (Chenodeoxycholic Acid) must follow specific regulatory conditions to maintain the product's quality and stability.

Storage Requirements

The medicine must be stored at a temperature not exceeding 30°C. To ensure the protection from moisture, the capsules should be kept in their original package.

Child Safety and Disposal

It is mandatory to keep this medicine out of the sight and reach of children.

Do not use the product after the expiry date printed on the carton. Any unused or expired medicine and waste material must be disposed of in accordance with local pharmaceutical waste requirements.

Хенофальк